BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology & Therapeutics (AOPT 2019...
March 04 2019 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, announced
today that Francois Binette, PhD, Senior Vice President and Global
Head of Product Development at BioTime, Inc., will present the 14th
Annual Scientific Meeting of the Association For Ocular
Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 at 1pm
EDT, as part of Session 12: “Disruptive Technologies: Ophthalmic
Tools and Methods That Have Changed The Ways We See The Eye”. AOPT
2019 will be held March 7-10. 2019 at the Hotel Monteleone in New
Orleans, LA. Dr. Binette’s presentation is entitled: “A Platform to
Take on the Entire Progressive Retinal Degeneration Disease
Continuum,” and will describe the wide range of potential
ophthalmic indications BioTime’s proprietary pluripotent stem cell
technology could address.
The Association for Ocular Pharmacology and Therapeutics
(AOPT)
The Association for Ocular Pharmacology and Therapeutics is a
global not-for-profit organization for scientists and individuals
from all disciplines related to ocular pharmacology and its
therapeutic applications. AOPT has a diverse, multi-national
membership composed of preclinical and clinical scientists,
students, and healthcare professionals. Members are from academic
institutions, pharma and biotech industries, device companies,
clinics and private practice. To achieve its mission the society
organizes biennial conferences and provides editorial leadership
for the peer-reviewed Journal of Ocular Pharmacology and
Therapeutics. For more information, please visit www.aopt.org or
connect with the association on Facebook or LinkedIn.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused
on the development and commercialization of novel therapies for the
treatment of degenerative diseases. BioTime’s pipeline is based on
two platform technologies which encompass cell replacement and
cell/drug delivery. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium transplant
therapy in Phase 2 development for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the
developed world. BioTime’s lead cell delivery clinical program is
Renevia®, an investigational medical device being developed as an
alternative for whole adipose tissue transfer procedures.
BioTime common stock is traded on the NYSE American and TASE
under the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, and YouTube. To receive
ongoing BioTime corporate communications, please click on
the following link to join the Company’s email alert
list: http://news.biotime.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190304005290/en/
BioTime Inc. IRIoana C. Honeir@biotimeinc.com(510)
871-4188
Solebury Trout IRGitanjali Jain
OgawaGogawa@troutgroup.com(646) 378-2949
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024